磷酸氯喹在加速88例普通型新型冠状病毒肺炎患者核酸转阴的临床观察

doi:10.3969/j.issn.1006⁃5725.2020.20.003

实用医学杂志 ›› 2020, Vol. 36 ›› Issue (20): 2759-2762.doi: 10.3969/j.issn.1006⁃5725.2020.20.003

• 新型冠状病毒肺炎专栏 • 上一篇下一篇

磷酸氯喹在加速88例普通型新型冠状病毒肺炎患者核酸转阴的临床观察

李娜1 谢甜1 魏晓芬2 易省阳1 曹一秋1 蒋思怡2 余雪涛3

1海南省人民医院重症医学科（海口570311）；2 深圳市第三人民医院重症医学科（广东深圳518100）；3深圳市龙岗区人民医院重症医学科（广东深圳518100）

出版日期:2020-10-20 发布日期:2020-10-25
通讯作者: 余雪涛E⁃mail：yxt1066@sina.cn

Chloroquine phosphate accelerates the conversion of nucleic acid to negative in 88 common COVID⁃19 pa⁃tients

LI Na*，XIE Tian，WEI Xiaofen，YI Shengyang，CAO Yiqiu，JIANG Siyi，YU Xuetao.

*Intensive CareUnit，Hainan General Hospital，Haikou 570311，China

Online:2020-10-20 Published:2020-10-25
Contact: YU Xuetao E⁃mail：yxt1066@sina.cn

摘要/Abstract

摘要：

目的探讨磷酸氯喹在加速普通型新型冠状病毒肺炎（coronavirus infectious disease 2019，COVID⁃19）患者核酸转阴的临床疗效。方法纳入2020年2月21日至3月8日在湖北省洪湖市第四人民医院确诊为普通型COVID⁃19 的88 例患者为研究对象。据知情同意原则分为治疗组（56 例）和对照组（32例）。对两组患者入组后到鼻咽拭子核酸检测第1次转为阴性的时间、第1次转阴时病程天数、住院时间及住院费用进行比较，对治疗组用药前后血白细胞、淋巴细胞计数、肝肾功能进行比较，对比治疗组不同年龄段用药后核酸检测第1次转为阴性的时间、第1次转阴时病程天数。结果治疗组鼻咽拭子核酸检测第1次转阴时间、转阴时病程天数、住院时间及住院费用均明显小于对照组。出院后复查核酸检测复阳率明显低于对照组，差异有统计学意义（P＜0.05）。治疗组用药前后血白细胞、淋巴细胞计数和肝肾功能差异均无统计学意义（P＞0.05）。治疗组中A组（18岁≤ 年龄< 35岁）、B组（35岁≤ 年龄< 50岁）核酸检测第1次转为阴性的时间、第1次核酸检测转阴时病程天数均比C组（50岁≤ 年龄≤ 65岁）缩短，差异有统计学意义（P＜0.05），A组与B组比较差异无统计学意义（P＞0.05）。结论磷酸氯喹可以显著加快普通型COVID⁃19患者鼻咽拭子核酸检测转阴时间，缩短病程、住院时间，减少住院费用且核酸复阳发生率低，用药不良反应少，磷酸氯喹的疗效可能受年龄因素影响。

关键词: 磷酸氯喹, 新型冠状病毒肺炎, 核酸, 疗效

Abstract:

Objective To investigate the clinical efficacy of chloroquine phosphate in accelerating thenegative conversion of nucleic acid in patients with common COVID⁃19. Methods From February 21 to March 8，2020，88 patients with common COVID⁃19 in the Fourth People′s Hospital of Honghu City，Hubei Province，were included in the study. According to the principle of informed consent，they were divided into the treatmentgroup（n = 56）and the control group（n = 32）. We compared the time of first conversion to be negative of novelcoronavirus nucleic acid and the total duration of sickness，hospital stay and hospitalization expenses between thegroups. Within the treatment group we compared counts of white blood cells and lymphocytes，functions of liverand kidney before and after chloroquine phosphate treatment as well as the curative effect in patients of differentage groups. Results Compared with the control group，the patients in the treatment group experienced signifi⁃cantly quicker negative conversion of COVID⁃19 nucleic acid，shorter hospital stay and less costs and the rate ofrecovered patients tested positive for the coronavirus was significantly lower（P < 0.05）. However，the counts ofwhite blood cells and lymphocytes，functions of liver and kidney showed no significant differences before andafter treatment with chloroquine phosphate. In the treatment group，the time when the nasopharyngeal swab nucleicacid test turned negative for the first time and the first time when the patients in the group aged between 18 to 35years and the group aged between 35 and 50 years were significantly shorter than that in the group aged between50 to 65（P < 0.05）. There was no significant difference between the groups aged 18 to 35 years and 35 ~ 50years（P > 0.05）. Conclusion Chloroquine phosphate can significantly accelerate negative conversion of nucleic acid in patients with common COVID⁃19，reduce total duration of sickness and the length of hospital stay，lowerthe hospitalization expenses，reduce the rate of recovered patients tested positive again and drug adverse reac⁃tions，but the efficacy of chloroquine phosphate may be influenced by patients′ age.

Key words: chloroquine phosphate, COVID?19, nucleic acid, efficacy

李娜, 谢甜, 魏晓芬, 易省阳, 曹一秋, 蒋思怡, 余雪涛. 磷酸氯喹在加速88例普通型新型冠状病毒肺炎患者核酸转阴的临床观察[J]. 实用医学杂志, 2020, 36(20): 2759-2762.

LI Na, XIE Tian, WEI Xiaofen, YI Shengyang, CAO Yiqiu, JIANG Siyi, YU Xuetao. Chloroquine phosphate accelerates the conversion of nucleic acid to negative in 88 common COVID⁃19 pa⁃tients[J]. The Journal of Practical Medicine, 2020, 36(20): 2759-2762.

[1]	刘茜,刘晓娜,李超,冼锐,崔立红. 不同方案治疗幽门螺杆菌感染合并小肠细菌过度生长的疗效分析[J]. 实用医学杂志, 2024, 40(9): 1303-1308.
[2]	王诗云,唐占英,林捷,陈倩,李方语,杨正权,胡志俊. COMP基因突变对超声引导下齿钩针刀治疗腕管综合征的临床疗效及对预后的影响[J]. 实用医学杂志, 2024, 40(8): 1126-1131.
[3]	党富涛,唐映梅,付海艳,李焕龙,徐加敏,谭绪. 非生物型人工肝支持系统治疗原发性胆汁性胆管炎患者的临床疗效及预后影响[J]. 实用医学杂志, 2024, 40(7): 955-961.
[4]	程魁红,赵刚,张锡武,陈状,江澈,武肖娜,罗高权,徐承澍. 血流导向装置与传统支架治疗颈内动脉眼动脉段未破裂动脉瘤的疗效[J]. 实用医学杂志, 2024, 40(7): 979-983.
[5]	王秀英,彭炳蔚,朱海霞,李小晶,宁书尧,陈文雄,冯芳媚. 儿童睡眠中癫痫性电持续状态脑电图特点与疗效的相关性[J]. 实用医学杂志, 2024, 40(4): 526-531.
[6]	宁燕虹,徐苑珊,李晓华,李仕华,杨桢华,廖蕴华,潘玲. 沙库巴曲缬沙坦治疗慢性肾脏病5期难治性高血压患者的临床观察[J]. 实用医学杂志, 2024, 40(4): 543-548.
[7]	赵健,刘松杰,张观朝,沈裕厚,李凤臣,徐兵. 着丝粒蛋白F、miR-1-3p在中晚期胃癌患者血清中的表达及与预后的相关性[J]. 实用医学杂志, 2024, 40(3): 365-370.
[8]	刘岩,徐丽娟,陈思歧,李艳红. 阳明经穴针刺法联合基于“治痿独取阳明”理论针推治疗吉兰-巴雷综合征的临床效果[J]. 实用医学杂志, 2024, 40(3): 406-411.
[9]	张映媛,牟春燕,许丹青,王远珍,常丽仙,刘春云,李卫昆,魏红艳,刘立. 艾米替诺福韦和富马酸替诺福韦对治疗乙肝肝纤维化的临床疗效比较[J]. 实用医学杂志, 2024, 40(22): 3215-3220.
[10]	王璇璐,胡颖,彭年春,许婧,何娟,肖帮惠,王睿,徐毅,张淼. 甲泼尼龙联合吗替麦考酚酯治疗中重度活动性Graves眼病[J]. 实用医学杂志, 2024, 40(21): 3067-3075.
[11]	王益,徐彬,陈杨达豪,徐卫星,盛红枫. 微创内镜辅助下颈椎前路减压融合术治疗神经根型颈椎病的疗效[J]. 实用医学杂志, 2024, 40(20): 2880-2887.
[12]	文贤,曾显峰,苏蕊雅. 伊伐布雷定片联合左西孟旦在急性心肌梗死合并心力衰竭患者中的应用[J]. 实用医学杂志, 2024, 40(2): 242-247.
[13]	王艳平,高文慧,伍艳婷,杨俊,周毅,简晓顺. 肿瘤患者中性粒细胞缺乏伴发热临床疗效的影响因素分析[J]. 实用医学杂志, 2024, 40(18): 2597-2601.
[14]	孙晓利,范慧洁. 血清miR-23a、miR-150、miR-150-5p水平与糖尿病性骨质疏松症的相关性[J]. 实用医学杂志, 2024, 40(16): 2244-2249.
[15]	袁胜芳,王布,项保利,赵建清,沈晶晶,张志华. 外周血循环肿瘤DNA预测晚期非小细胞肺癌免疫治疗疗效及预后价值[J]. 实用医学杂志, 2024, 40(15): 2110-2115.

磷酸氯喹在加速88例普通型新型冠状病毒肺炎患者核酸转阴的临床观察

Chloroquine phosphate accelerates the conversion of nucleic acid to negative in 88 common COVID⁃19 pa⁃tients

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价